JPWO2022015656A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022015656A5 JPWO2022015656A5 JP2023501559A JP2023501559A JPWO2022015656A5 JP WO2022015656 A5 JPWO2022015656 A5 JP WO2022015656A5 JP 2023501559 A JP2023501559 A JP 2023501559A JP 2023501559 A JP2023501559 A JP 2023501559A JP WO2022015656 A5 JPWO2022015656 A5 JP WO2022015656A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- glycine
- antibody
- absent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023214174A JP7776485B2 (ja) | 2020-07-13 | 2023-12-19 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051172P | 2020-07-13 | 2020-07-13 | |
| US63/051,172 | 2020-07-13 | ||
| US202163154531P | 2021-02-26 | 2021-02-26 | |
| US63/154,531 | 2021-02-26 | ||
| PCT/US2021/041304 WO2022015656A1 (en) | 2020-07-13 | 2021-07-12 | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023214174A Division JP7776485B2 (ja) | 2020-07-13 | 2023-12-19 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534437A JP2023534437A (ja) | 2023-08-09 |
| JPWO2022015656A5 true JPWO2022015656A5 (enExample) | 2024-07-19 |
Family
ID=77168491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501559A Pending JP2023534437A (ja) | 2020-07-13 | 2021-07-12 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
| JP2023214174A Active JP7776485B2 (ja) | 2020-07-13 | 2023-12-19 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023214174A Active JP7776485B2 (ja) | 2020-07-13 | 2023-12-19 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220072141A1 (enExample) |
| EP (2) | EP4406608A3 (enExample) |
| JP (2) | JP2023534437A (enExample) |
| KR (2) | KR20240038138A (enExample) |
| CN (2) | CN118085100A (enExample) |
| AU (2) | AU2021308190A1 (enExample) |
| BR (1) | BR112023000489A2 (enExample) |
| CA (1) | CA3183184A1 (enExample) |
| CL (1) | CL2023000098A1 (enExample) |
| CO (1) | CO2023001402A2 (enExample) |
| IL (2) | IL299153A (enExample) |
| MA (1) | MA71650A (enExample) |
| MX (2) | MX2023000544A (enExample) |
| WO (1) | WO2022015656A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3166732A1 (en) * | 2020-01-22 | 2021-07-29 | Medimmune Limited | Compounds and conjugates thereof |
| EP4223318A4 (en) * | 2020-09-30 | 2024-12-18 | Duality Biologics (Suzhou) Co., Ltd. | Antitumor compound, and preparation method therefor and use thereof |
| CN118829449A (zh) * | 2022-01-12 | 2024-10-22 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| US20250114472A1 (en) * | 2022-01-24 | 2025-04-10 | Beijing Chempion Biotechnology Co., Ltd. | Conjugate and use thereof |
| EP4489791A1 (en) * | 2022-03-09 | 2025-01-15 | Merck Patent GmbH | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| WO2023217064A1 (zh) * | 2022-05-09 | 2023-11-16 | 同宜医药（苏州）有限公司 | 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用 |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| IL319866A (en) * | 2022-09-30 | 2025-05-01 | Beigene Switzerland Gmbh | Ligand-drug conjugates of exatacan analogs and their medical use |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| KR20250133813A (ko) | 2022-12-21 | 2025-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법 |
| EP4661914A1 (en) | 2023-02-09 | 2025-12-17 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates via inverse electron demand diels-alder reactions |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025038752A1 (en) * | 2023-08-14 | 2025-02-20 | Cancer Targeted Technology Llc | Psma binding ligand-linker conjugates and methods for use thereof |
| EP4537854A1 (en) * | 2023-10-04 | 2025-04-16 | Formosa Laboratories, Inc. | Compound for conjugation, conjugate and pharmaceutical composition comprising the same |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025103474A1 (zh) * | 2023-11-17 | 2025-05-22 | 成都康弘生物科技有限公司 | 双毒素抗体药物偶联物及其用途 |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA2008368C (en) | 1989-01-24 | 2003-04-08 | Jeffrey Greve | Soluble molecule related to but distinct from icam-1 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| CA2481503A1 (en) | 2002-04-05 | 2003-10-23 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| WO2005079490A2 (en) | 2004-02-13 | 2005-09-01 | Nuvelo, Inc. | Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| DK2167963T3 (da) | 2007-05-23 | 2019-06-24 | Ventana Med Syst Inc | Polymerbærere til immunhistokemi og in situ-hybridisering |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| EP2326349B1 (en) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| TWI540136B (zh) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CA3250882A1 (en) | 2010-08-02 | 2025-11-29 | Regeneron Pharamaceuticals, Inc. | Mice that Make Binding Proteins Comprising VL Domains |
| MX345538B (es) | 2011-05-27 | 2017-02-03 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2013055990A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| EP2818480B1 (en) * | 2012-02-24 | 2020-08-26 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| IL302494B2 (en) | 2012-10-11 | 2024-11-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates and methods for their preparation |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| AU2014283185B2 (en) * | 2013-06-21 | 2019-05-02 | Araris Biotech Ltd. | Enzymatic conjugation of polypeptides |
| JP6608823B2 (ja) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
| SMT202500030T1 (it) * | 2014-01-31 | 2025-03-12 | Daiichi Sankyo Co Ltd | Coniugato anticorpo anti-her2-farmaco |
| JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| PT3789042T (pt) * | 2014-04-10 | 2025-01-14 | Daiichi Sankyo Europe Gmbh | Método para produzir conjugado anticorpo-fármaco anti-her3 |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| CA2978942A1 (en) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| KR101757977B1 (ko) | 2015-06-26 | 2017-07-13 | 아주대학교산학협력단 | 바이오 잉크의 제조방법 및 3d 프린터 적용 |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| MY199468A (en) * | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| KR20250114431A (ko) * | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018182341A1 (ko) | 2017-03-29 | 2018-10-04 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
| CA3063872A1 (en) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| US11629122B2 (en) | 2017-05-24 | 2023-04-18 | The Board Of Regents Of The University Of Texas System | Linkers for antibody drug conjugates |
| CA3067829A1 (en) * | 2017-06-23 | 2018-12-27 | VelosBio Inc. | Ror1 antibody immunoconjugates |
| KR102871690B1 (ko) | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| KR20210008008A (ko) * | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| SG11202010496WA (en) * | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| US12209180B2 (en) * | 2018-11-20 | 2025-01-28 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists |
| WO2020245229A1 (en) * | 2019-06-03 | 2020-12-10 | Synaffix B.V. | Acetal-based cleavable linkers |
| CN110974975B (zh) * | 2019-12-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
| AU2021228225A1 (en) * | 2020-02-28 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
-
2021
- 2021-07-12 IL IL299153A patent/IL299153A/en unknown
- 2021-07-12 IL IL309173A patent/IL309173A/en unknown
- 2021-07-12 MA MA71650A patent/MA71650A/fr unknown
- 2021-07-12 US US17/373,524 patent/US20220072141A1/en active Pending
- 2021-07-12 BR BR112023000489A patent/BR112023000489A2/pt unknown
- 2021-07-12 MX MX2023000544A patent/MX2023000544A/es unknown
- 2021-07-12 JP JP2023501559A patent/JP2023534437A/ja active Pending
- 2021-07-12 KR KR1020247008244A patent/KR20240038138A/ko active Pending
- 2021-07-12 CN CN202410175152.9A patent/CN118085100A/zh active Pending
- 2021-07-12 CA CA3183184A patent/CA3183184A1/en active Pending
- 2021-07-12 WO PCT/US2021/041304 patent/WO2022015656A1/en not_active Ceased
- 2021-07-12 EP EP24176032.1A patent/EP4406608A3/en active Pending
- 2021-07-12 CN CN202180062762.2A patent/CN116390771A/zh active Pending
- 2021-07-12 AU AU2021308190A patent/AU2021308190A1/en active Pending
- 2021-07-12 KR KR1020237004637A patent/KR20230038738A/ko active Pending
- 2021-07-12 EP EP21749495.4A patent/EP4178625A1/en active Pending
-
2023
- 2023-01-10 MX MX2024003180A patent/MX2024003180A/es unknown
- 2023-01-10 CL CL2023000098A patent/CL2023000098A1/es unknown
- 2023-02-09 CO CONC2023/0001402A patent/CO2023001402A2/es unknown
- 2023-11-21 US US18/516,454 patent/US20240252661A1/en active Pending
- 2023-12-19 JP JP2023214174A patent/JP7776485B2/ja active Active
-
2024
- 2024-02-09 AU AU2024200822A patent/AU2024200822A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022015656A5 (enExample) | ||
| CN112261954B (zh) | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 | |
| JP7431261B2 (ja) | 自己安定化リンカー結合体 | |
| TWI811726B (zh) | 改良配體-藥物結合物之藥物動力學之聚乙二醇化藥物連接子 | |
| TWI680765B (zh) | 自行穩定之接合劑共軛物 | |
| KR20210053871A (ko) | 캄프토테신 접합체 | |
| AU2015210578B2 (en) | Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof | |
| CN108779127A (zh) | 美登素类化合物衍生物、其偶联物和使用方法 | |
| BR112020020466A2 (pt) | Conjugados de peptídeo de camptotecina | |
| JP2017514905A5 (enExample) | ||
| EP4406606A2 (de) | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren g | |
| JP2018502844A (ja) | Ｋｓｐ阻害剤の脱グリコシル化抗ｔｗｅａｋｒ抗体との抗体薬物複合体（ａｄｃ類） | |
| CN106255513A (zh) | 用于药物偶联物的含磺酰胺连接系统 | |
| KR20180030993A (ko) | 항체-약물 접합체 중의 공유결합 링커 및 이의 제조방법 및 사용방법 | |
| PL172837B1 (pl) | Preparat farmaceutyczny zawierajacy koniugaty tioeterowe PL PL PL PL PL | |
| JP2018520130A (ja) | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体 | |
| CN113456829A (zh) | 新型亲水连接体和其在配体-药物共轭偶联物上的应用 | |
| JP2018525334A (ja) | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体 | |
| JP7397058B2 (ja) | 細胞障害性薬物の複合体及び前記複合体のプロドラッグの形態 | |
| JPWO2019232449A5 (enExample) | ||
| JP2024178320A (ja) | チオール多重リンカーを有するａｄｃ | |
| CN119095625A (zh) | 抗体-药物偶联物 | |
| CN119156232A (zh) | 抗体-药物偶联物前体及其合成中间体 | |
| WO2022154127A1 (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| JPWO2020089687A5 (enExample) |